乳酸酸酯KLDS 1.0738对肠道菌群和TLR4表达在β-乳球蛋白诱导的过敏小鼠模型中的调节作用。
摘要来源:摘要来源:
emplergol Immunopathol(MADR)。 2019年8月30日。EPUB 2019年8月30日。PMID: 31477403“> 31477403 31477403 Zhang,y li,s-s yu,h-y wu,z chen,a-l li,p du,c li
文章隶属关系:w-w-w ni
摘要:
span a> span> spann sprantiations:基因测序。血清细胞因子产生和TLR4/NF-κB mRNA expression in the colon tissues were measured by ELISA kit and quantitative RT-PCR, respectively.
RESULTS: The results showed that Lap KLDS 1.0738 pretreatment attenuatedβ-Lg-induced hypersensitivity, accompanied with a diminished expression of TLR4/NF-κB信号传导。此外,口服KLDS 1.0738改善了粪便菌群的丰富性和多样性,其特征在于较少的蛋白质细菌状态和螺旋杆菌科,而高较高的菌属和lachnospiraceae家族比过敏症组。值得注意的是,TLR4/NF-κB表达与过敏群中的螺旋杆菌家族呈正相关,但与lachnospileceae,ruminococcacaceae和抗炎细胞因子水平的家族呈负相关。在TLR4/NF-κB表达与组胺,总IgE和促炎细胞因子的产生之间观察到了阳性相关性。
CONCLUSIONS: Intake of Lap KLDS 1.0738 can influence the gut bacterial composition, which might result in recognizing TLRs signaling so as to inhibit allergic response.